Dr. Lin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2008 Health Campus Dr
Harrisonburg, VA 22801Phone+1 540-689-7000Fax+1 540-689-7001
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009
- Steward Carney HospitalResidency, Internal Medicine, 2003 - 2006
- Marshall UniversityMA, Biomedical Science, 1995 - 1997
- Shanghai Medical University Graduate SchoolMS, Pathophysiology, 1989 - 1992
- Zhejiang Medical UniversityClass of 1986
Certifications & Licensure
- VA State Medical License 2022 - 2026
- DC State Medical License 2016 - 2022
- PA State Medical License 2009 - 2016
- MD State Medical License 2006 - 2010
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
- Dean's Award TJU, 2012
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2013
- Join now to see all
Clinical Trials
- Digoxin for Recurrent Prostate Cancer Start of enrollment: 2010 Sep 01
- Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer Start of enrollment: 2011 Jun 01
- Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer Start of enrollment: 2011 Sep 22
- Join now to see all
Publications & Presentations
PubMed
- 19 citationsImproved prognostic stratification using circulating tumor cell clusters in patients with metastatic castration-resistant prostate cancerChun Wang, Zhenchao Zhang, Weelic Chong, Rui Luo, Ronald E. Myers
Cancers. 2021-01-13 - 86 citationsEffects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based StudyYinzhi Lai, Chun Wang, Jesse Civan, Juan P. Palazzo, Zhong Ye
Gastroenterology. 2016-05-01 - 123 citationsAntiobesity Pharmacotherapy: New Drugs and Emerging TargetsGilbert W. Kim, Jieru E. Lin, Erik S. Blomain, Scott A. Waldman
Clinical Pharmacology and Therapeutics. 2013-10-08
Journal Articles
- Immune Biomarkers of Treatment Failure for a Patient with Renal Cell Carcinoma on a Phase I Trial of Pembrolizumab plus RadiotherapyAlexander G, Palmer J, Tuluc M, Lin J, D Craig Hooper DC, Lu B, Journal for ImmunoTherapy of Cancer, 1/1/2015
- Change in PSA Velocity Is a Predictor of Overall Survival in Men with Biochemically-recurrent Prostate Cancer Treated with Nonhormonal Agents: Combined Analysis of Fou...Suzman DL, Zhou XC, Zahurak ML, Lin J, Antonarakis ES, Prostate Cancer Prostatic Dis, 1/1/2015
- An Open Label Randomized Phase II Study of Pasireotide with or without Everolimus in Castrate-resistant Chemotherapy-naive Prostate Cancer PatientsLin J, Deng A, Hoffman-Censits J, Gibney G, Hyslop T, Miller B, Kilpatrick D, Jabbour S, Kelly WK, Cancer Treatment Communications, 1/1/2015
- Join now to see all
Abstracts/Posters
- A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate...Jianqing Lin, Ashwin R. Sama, Jean. H. Hoffman-Censits, Brooke Kennedy, Debraoh Kilpatrick, Ye Zhong, Hushan Yang, Zhaomei Mu, Benjamin E. Leiby, Nancy Lewis, Massimo ..., 2016 GU ASCO Symposium, 2016
Professional Memberships
- Member
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: